Skip to main navigation Skip to search Skip to main content

Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model

  • Kentaro Miyake
  • , Tasuku Kiyuna
  • , Masuyo Miyake
  • , Kei Kawaguchi
  • , Zhiying Zhang
  • , Sintawat Wangsiricharoen
  • , Sahar Razmjooei
  • , Hiromichi Oshiro
  • , Takashi Higuchi
  • , Yunfeng Li
  • , Scott D. Nelson
  • , Takashi Murakami
  • , Yukihiko Hiroshima
  • , Takafumi Kumamoto
  • , Ryusei Matsuyama
  • , Michael Bouvet
  • , Shree Ram Singh
  • , Sant P. Chawla
  • , Itaru Endo
  • , Robert M. Hoffman

Research output: Contribution to journal › Article › peer-review

Abstract

There are no effective treatments for leiomyosarcoma (LMS) spreading intraabdominally. The aim of this study was to develop precision chemotherapy for recurrent peritoneal LMS metastases in a patient-derived orthotopic xenograft (PDOX) model. The LMS PDOX models were established orthotopically on the dome of the bladder of nude mice. The LMS PDOX models were randomized into 6 groups when the tumor volume reached 80 mm 3 : G1: untreated control; G2: doxorubicin (DOX) (DOX: i.p., 3 mg/kg, weekly, 3 weeks); G3: DOX combined with olaratumab (OLA) (DOX: i.p., 3 mg/kg, weekly, 3 weeks; OLA: i.p., 40 mg/kg, 3 times/week, 3 weeks); G4: gemcitabine (GEM) combined with docetaxel (DOC) (GEM: i.p., 100 mg/kg, weekly, 3 weeks; DOC: i.p., 20 mg/kg, weekly, 3 weeks); G5: pazopanib (PAZ) (PAZ: p.o., 100 mg/kg, daily, 3 weeks); G6: palbociclib (PAL) (PAL: p.o., 100 mg/kg, daily, 3 weeks). All mice were sacrificed on day 22. Body weight was assessed twice a week. Tumor volume was measured on day 0 and day 22. Although all regimens had a significant efficacy compared to the untreated group (P < 0.001), only GEM combined with DOC regressed the tumor significantly (P < 0.001), suggesting GEM combined with DOC has clinical potential for this LMS patient.

Original languageEnglish
Pages (from-to)1041-1046
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume509
Issue number4
DOIs
Publication statusPublished - 19-02-2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model'. Together they form a unique fingerprint.

Cite this